Advertisement

Zeitschrift für Rheumatologie

, Volume 71, Issue 7, pp 604–618 | Cite as

Systematische Literaturrecherche für die S1-Leitlinie zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis

  • K. AlbrechtEmail author
  • K. Krüger
  • U. Müller-Ladner
  • J. Wollenhaupt
Originalien

Zusammenfassung

Hintergrund

Ausgangspunkt der neuen S1-Leitlinie waren die 2010 erschienenen EULAR Recommendations zum Management der rheumatoiden Arthritis (RA), die nach umfangreichen systematischen Literaturrecherchen (SLR) evidenzbasiert erstellt worden sind. Die SLR wurde für die deutschen Empfehlungen aktualisiert und wird in ihrer Methodik vorgestellt.

Methodik

Die SLR wurde für den Zeitraum von Januar 2009 bis Ende August 2011 durchgeführt. Es wurden alle kontrollierten Studien eingeschlossen, die die krankheitsmodifizierende Therapie der RA hinsichtlich ihrer Wirksamkeit auf Klinik, Funktion und Struktur untersucht haben.

Ergebnisse

Von 6869 gesichteten Arbeiten wurden 138 Artikel und 56 Abstracts für die Erstellung der Leitlinie berücksichtigt. Auf einem Konsensustreffen wurden die Ergebnisse der SLR vorgestellt. Auf dieser Grundlage formulierte das Expertengremium modifizierte Empfehlungen und verabschiedete diese mittels Konsensus.

Schlussfolgerungen

Mithilfe der aktualisierten SLR konnten wesentliche neue Daten im Entscheidungsprozess für die neue S1-Leitlinie zur medikamentösen Therapie der RA berücksichtigt werden.

Schlüsselwörter

Rheumatoide Arthritis Systematische Literaturrecherche Biologika DMARDs Glukokortikoide 

Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis

Abstract

Background

On behalf of the German association of Rheumatology national experts developed guidelines for the medical treatment of rheumatoid arthritis (RA) based on the EULAR recommendations for the management of RA published in 2010. Current evidence was provided with an update of the systematic literature review (SLR). The methods and results of the SLR are presented in this article.

Materials and methods

An update of the EULAR SLR for the medical treatment of RA was performed from January 2009 to August 2011. The SLR assessed all controlled studies dealing with the outcome in clinical aspects, function and structure of disease modifying treatment of RA.

Results

Out of 6,869 screened publications, 138 articles and 56 abstracts were considered in the development of the German guidelines on the treatment of RA. A modified set of recommendations was approved in a consensus of national experts.

Conclusion

A systematic literature research provided current evidence for the German recommendations on the sequential medical treatment of RA.

Keywords

Rheumatoid arthritis Systematic literature research Biological agents Disease-modifying antirheumatic drugs Glucocorticoids 

Notes

Danksagung

Die Durchführung der SLR wurde von der DGRh finanziert mit Unterstützung durch ein „unrestricted grant“ folgender korporativer Mitglieder der DGRh: Abbott GmbH & Co.KG, Chugai Pharma Marketing Ltd., Pfizer Pharma GmbH, Roche Pharma AG, Sanofi-Aventis Deutschland GmbH, UCB Pharma GmbH.

Interessenkonflikt

Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: Vortragshonorare von Abbott (K.A.); Beratungstätigkeit/Vortragshonorare von Abbott, BMS, MSD, Mundipharma, Pfizer, UCB, Roche (K.K); Abbott, BMS, Chugai, MSD, Pfizer, Roche, UCB (U.M.-L.); Abbott, BMS, Chugai, MSD, Pfizer, Roche, UCB (J.W.).

Literatur

  1. 1.
    Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumour necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189PubMedCrossRefGoogle Scholar
  2. 2.
    AWMF online. Das Portal der wissenschaftlichen Medizin. http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/060–004.htmlGoogle Scholar
  3. 3.
    Bakker MF, Jacobs JW, Welsing PM et al (2011) Low-dose prednisone inclusion into a MTX-based tight control strategy for early rheumatoid arthritis: better control of disease and erosive joint damage. Results from the double-blind randomized CAMERA-II trial. Ann Rheum Dis 70(Suppl3):114CrossRefGoogle Scholar
  4. 4.
    Bakker MF, Jacobs JW, Welsing PM et al (2011) Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 70:1099–1103PubMedCrossRefGoogle Scholar
  5. 5.
    Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522–529CrossRefGoogle Scholar
  6. 6.
    Bathon J, Robles M, Ximenes AC (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70:1949–1956PubMedCrossRefGoogle Scholar
  7. 7.
    Benedict A, Vanness DJ, Roy S, Cifaldi MA (2010) Comparative effectiveness of biologic therapies for treating rheumatoid arthritis (RA) in patients who failed an anti–tumor necrosis factor agent: a meta-regression analysis. Arthritis Rheum 62(Suppl 10):2266Google Scholar
  8. 8.
    Bergman GJ, Hochberg MC, Boers M et al (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441PubMedCrossRefGoogle Scholar
  9. 9.
    Bird, Paul, Griffiths, Hedley et al (2010) The Optimising Patient Outcomes in Australian RheumatoLogy [OPAL] Consortium, multi-centre, cross-sectional, observational study of the safety of methotrexate and leflunomide in combination in the treatment of patients with rheumatoid arthritis the SMILE Study. Safety of methotrexate in combination with leflunomide. Arthritis Rheum 62(Suppl10):319Google Scholar
  10. 10.
    Breedveld F, Keystone E, Heijde D van der et al (2011) Initial combination therapy with adalimumab plus methotrexate leads to better long-term outcomes in patients with early rheumatoid arthritis: 8-year results of the premier trial. Ann Rheum Dis 70(Suppl 3):254CrossRefGoogle Scholar
  11. 11.
    Buttgereit F, Doering G, Schaeffler A et al (2010) Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 69:1275–1280PubMedCrossRefGoogle Scholar
  12. 12.
    Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374–377PubMedCrossRefGoogle Scholar
  13. 13.
    Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70:1575–1580PubMedCrossRefGoogle Scholar
  14. 14.
    Curtis JR, Xie F, Chen L et al (2011) The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70:1401–1406PubMedCrossRefGoogle Scholar
  15. 15.
    Devine EB, Alfonso-Cristancho R, Sullivan SD (2011) Effectiveness of biologic therapies for rheumatoid arthritis: an indireact comparisons approach. Pharmacotherapy 31:39–51PubMedCrossRefGoogle Scholar
  16. 16.
    Dirven L, Broek M van den, Klarenbeek NB et al (2011) Clinical and radiological outcomes of four DAS driven treatment strategies: 7-year results of the BeSt study. Ann Rheum Dis 70(Suppl 3):642CrossRefGoogle Scholar
  17. 17.
    Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Ann Rheum Dis 70(Suppl 3):599CrossRefGoogle Scholar
  18. 18.
    Dougados M, Huizinga T, Sheeran T et al (2011) Tocilizumab plus methotrexate does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results oft the ACT-RAY study. Ann Rheum Dis 70(Suppl 3):73Google Scholar
  19. 19.
    Dreyer L, Mellemkjær L, Hetland ML (2011) No increased cancer risk in patients with rheumatoid arthritis, psoriatic arthritis or other arthritides treated with anti-tumour necrosis factor agents – a long-term follow-up study from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(Suppl 3):410Google Scholar
  20. 20.
    Emery P, Fleischmann R, Heijde D van der et al (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63:1200–1210PubMedCrossRefGoogle Scholar
  21. 21.
    Emery P, Breedveld F, Heijde D van der et al (2010) Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 62:674–682PubMedCrossRefGoogle Scholar
  22. 22.
    Fedorenko E, Lukina GV, Sigidin YA et al (2011) Remission as the main goal of treatment in early rheumatoid arthritis (RA) patients: comparative efficacy of four treatment regimens. Ann Rheum Dis 70(Suppl 3):598Google Scholar
  23. 23.
    Finckh A, Dehler S, Gabay C et al (2009) The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 68:33–39PubMedCrossRefGoogle Scholar
  24. 24.
    Finckh A, Ciurea A, Brulhart L et al (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387–393PubMedCrossRefGoogle Scholar
  25. 25.
    Gaujoux-Viala C, Smolen JS, Landewe R et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004–1009PubMedCrossRefGoogle Scholar
  26. 26.
    Gómez-Reino J-J, Sanmartí R, Romero A-B, Monclus L (2010) Rituximab vs TNF-inhibitor cycling in patients Who previously failed to TNF-inhibitors: the MIRAR Study. Arthritis Rheum 62(Suppl 10):409CrossRefGoogle Scholar
  27. 27.
    Gorter SL, Bijlsma JW, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1010–1014PubMedCrossRefGoogle Scholar
  28. 28.
    Graudal N, Jürgens G (2010) Similar effects of disease-modifying antirheuamtic drugs, glucocorticoids and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 62:2852–2853PubMedCrossRefGoogle Scholar
  29. 29.
    Greenberg JD, Kremer JM, Curtis JR et al (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70:576–582PubMedCrossRefGoogle Scholar
  30. 30.
    Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380–386PubMedCrossRefGoogle Scholar
  31. 31.
    Hafstrem I, Albertsson K, Boonen A et al (2009) Remission achieved after 2 years treatment with low-dose prednisolone in addition to diseasemodifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 68:508–513CrossRefGoogle Scholar
  32. 32.
    Hetland ML, Stengaard-Pedersen K, Junker P et al (2010) Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomized CIMESTRA trial. Ann Rheum Dis 69:789–795CrossRefGoogle Scholar
  33. 33.
    Katchamart W, Trudeau J, Phumethum V, Bombardier C (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis. Cochrane database Syst Rev 4 ppCD008495Google Scholar
  34. 34.
    Kekow J, Müller-Ladner U, Schulze-Koops H et al (2010) Real life treatment with rituximab in TNF blocker non-responders is superior to treatment with a second TNF blocker. Arthritis Rheum 62(Suppl 10):406Google Scholar
  35. 35.
    Klarenbeek NB, Güler-Yüksel M, Kooij SM van der et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046PubMedCrossRefGoogle Scholar
  36. 36.
    Knevel R, Schoels M, Huizinga TWJ et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:987–994PubMedCrossRefGoogle Scholar
  37. 37.
    Komano Y, Tanaka M, Nanki T et al (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38:1258–1264PubMedCrossRefGoogle Scholar
  38. 38.
    Kremer J, Ritchlin C, Mendelsohn A et al (2010) Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 62:917–928PubMedCrossRefGoogle Scholar
  39. 39.
    Kristensen LE, Jakobsen AK, Bartels EM et al (2011) The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol 40:1–7PubMedCrossRefGoogle Scholar
  40. 40.
    Kuriya B, Arkema EV, Bykerk VP, Keystone EC (2010) Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 69:1298–1304PubMedCrossRefGoogle Scholar
  41. 41.
    Le Blay P, Mouterde G, Barnetche T, Combe B (2010) Risk of malignancy during Anti-TNF alfa therapy in patients with rheumatoid arthritis: systematic review and meta-analysis of registries, long-term extension studies and randomized controlled trials. Arthritis Rheum 62(Suppl 10):408CrossRefGoogle Scholar
  42. 42.
    Liberati A, Douglas G, Altman D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94PubMedGoogle Scholar
  43. 43.
    Lie E, Heijde D van der, Uhlig T et al (2011) Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 70:2103–2110PubMedCrossRefGoogle Scholar
  44. 44.
    Lunt M, Watson KD, Dixon WG et al (2010) No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145–3153PubMedCrossRefGoogle Scholar
  45. 45.
    Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98PubMedCrossRefGoogle Scholar
  46. 46.
    Machold KP, Landewe R, Smolen JS et al (2010) The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomized, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 69:495–502PubMedCrossRefGoogle Scholar
  47. 47.
    Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRefGoogle Scholar
  48. 48.
    Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheum 37:234–245PubMedCrossRefGoogle Scholar
  49. 49.
    Mercer LK, Davies R, Lunt M et al (2011) Risk of cancer in patients receiving non-biologic disease modifying therapy for rheumatoid arthritis: results from the BSR biologics register (BSRBR). Ann Rheum Dis 70(Suppl 3):456Google Scholar
  50. 50.
    Müller-Ladner U (2009) Unifying abbreviations for biologics in rheumatology-does the idea hold promise? Rheumatology 48:704PubMedCrossRefGoogle Scholar
  51. 51.
    Nam JL, Winthrop KL, Vollenhoven RF van et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976–986PubMedCrossRefGoogle Scholar
  52. 52.
    Nam JL, Villeneuve E, Conaghan PG et al (2011) A preliminary report of remission induction with two therapeutic strategies with infliximab or high dose intervenous steroids for the treatment of rheumatoid arthritis. Ann Rheum Dis 70(Suppl 3):121Google Scholar
  53. 53.
    Navarro-Sarrabia F, Ruiz-Montesinos D, Hernandez B et al (2009) DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMJ Muskuloskelet Disord 10:91CrossRefGoogle Scholar
  54. 54.
    Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 9:12–19CrossRefGoogle Scholar
  55. 55.
    OCEBM Levels of Evidence Working Group*. „The Oxford 2011 Levels of Evidence“. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o = 5653Google Scholar
  56. 56.
    Rantalaiho V, Korpela M, Hannonen P et al (2009) The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60:1222–1231PubMedCrossRefGoogle Scholar
  57. 57.
    Rigby W, Ferraccioli G, Greenwald M et al (2011) Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res 63:711–720CrossRefGoogle Scholar
  58. 58.
    Ruiz Garcia V, Jobanputra P, Burls A et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 16:CD007649Google Scholar
  59. 59.
    Salliot C, Finckh A, Katchamart W et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis Ann Rheum Dis 70:266–271Google Scholar
  60. 60.
    Salmon-Ceron D, Tubach F, Lortholary O et al (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616–623PubMedCrossRefGoogle Scholar
  61. 61.
    Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613–624PubMedCrossRefGoogle Scholar
  62. 62.
    Schoels M, Wong JB, Aletaha D, Smolen JS (2010) Comparative effectiveness of biological treatment options following tumor necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Arthritis Rheum 62(Suppl 10):1795Google Scholar
  63. 63.
    Sibilia J, Graninger W, Östör A et al (2011) Comparison of tocilizumab as monotherapy or with add-on DMARDs in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 70(Suppl 3):466Google Scholar
  64. 64.
    Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 20:CD008341Google Scholar
  65. 65.
    Singh JA, Christensen R, Wells GA (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 4 John Wiley & Sons, Ltd, Chichester. doi: 10.1002/14651858.CD007848Google Scholar
  66. 66.
    Singh JA, Beg S, Lopez-Olivo MA (2010) Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 7 John Wiley & Sons, Ltd, Chichester. doi: 10.1002/14651858.CD008331Google Scholar
  67. 67.
    Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975PubMedCrossRefGoogle Scholar
  68. 68.
    Smolen JS, Han C, Van Der Heijde D et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68(6):823–827PubMedCrossRefGoogle Scholar
  69. 69.
    Smolen JS, Emery, Ferraccioli GF et al (2011) Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIb study. Ann Rheum Dis 70(Suppl 3):259CrossRefGoogle Scholar
  70. 70.
    Smolen JS, Fleischmann R, Emery P et al (2011) The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 70(Suppl 3):259CrossRefGoogle Scholar
  71. 71.
    Soliman MM, Ashcroft DM, Watson KD et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589PubMedCrossRefGoogle Scholar
  72. 72.
    Soubrier M, Lukas C, Sibilia J et al (2011) Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 70:611–615PubMedCrossRefGoogle Scholar
  73. 73.
    Soubrier M, Puéchal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48:1429–1434PubMedCrossRefGoogle Scholar
  74. 74.
    Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856–1862PubMedCrossRefGoogle Scholar
  75. 75.
    Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5PubMedCrossRefGoogle Scholar
  76. 76.
    Tak PP, Rigby WF, Rubbert-Roth A et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39–46PubMedCrossRefGoogle Scholar
  77. 77.
    Tanaka Y, Harigai M, Takeuchi T et al (2011) Golimumab, a human anti-TNFα monoclonal antibody administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy: 24-week results of clinical and radiographic assessments. Ann Rheum Dis 70(Suppl 3):422Google Scholar
  78. 78.
    Todoerti M, Scire CA, Boffini N et al (2010) Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann NY Acad Sci 1193:139–145PubMedCrossRefGoogle Scholar
  79. 79.
    Van Dartel S, Fransen J, Kievit W et al (2011) The difference between adalimumab, infliximab and etanercept on the risk of serious infections in patients with rheumatoid arthritis: results from the DREAM registry. Ann Rheum Dis 70(Suppl 3):417Google Scholar
  80. 80.
    Van Tuyl LHD, Boers M, Lems WF et al (2010) Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807–812CrossRefGoogle Scholar
  81. 81.
    Vollenhoven RF van, Ernestam S, Geborek P et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374 459–466Google Scholar
  82. 82.
    Vermeer M, Kuper, IH, Hoekstra M et al (2010) Long-term remission in daily clinical practice: excellent 2 year results with treatment to target in very early rheumatoid arthritis, results of the DREAM remission induction cohort. Arthritis Rheum 62(Suppl 10):662Google Scholar
  83. 83.
    Verstappen SM, McCoy MJ, Roberts C et al (2010) Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 69:503–509PubMedCrossRefGoogle Scholar
  84. 84.
    Volkmann ER, Agrawal H, Maranian P, Furst DE (2010) Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med Insights 2:749–760Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • K. Albrecht
    • 1
    Email author
  • K. Krüger
    • 2
  • U. Müller-Ladner
    • 3
  • J. Wollenhaupt
    • 4
  1. 1.Deutsche Gesellschaft für RheumatologieBerlinDeutschland
  2. 2.Praxiszentrum Rheumatologie, MünchenMünchenDeutschland
  3. 3.Abteilung für Rheumatologie und klinische ImmunologieJustus-Liebig-Universität Giessen, Kerckhoff-KlinikBad NauheimDeutschland
  4. 4.Klinik für Rheumatologie und klinische ImmunologieSchön Klinik Hamburg EilbekHamburgDeutschland

Personalised recommendations